Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,163 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03685448 | ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)(UNICAB) | completed | Phase 2 | 35 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03967522 | Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases(CABRAMET) | completed | Phase 2 | 26 | Centre Leon BerardOTHER | 1 |
| Aug 8, 2025 |
| clinicaltrials |
| NCT03599713 | A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) | completed | Phase 2 | 107 | Incyte CorporationINDUSTRY | 12 | Aug 5, 2025 | clinicaltrials |
| NCT05480306 | Phase 2 Study of DKN-01 in Colorectal Cancer(DeFianCe) | completed | Phase 2 | 188 | Leap Therapeutics, Inc.INDUSTRY | 3 | Aug 3, 2025 | clinicaltrials |
| NCT05156970 | Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC | completed | Phase 2 | 81 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT02769832 | Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer | completed | Phase 2 | 32 | Muhammad FurqanOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT01356628 | A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer | completed | Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT01506973 | A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 119 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03795610 | IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 16 | Assuntina G. Sacco, MDOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT02678780 | Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors(TALENT) | completed | Phase 2 | 123 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 4 | Jul 24, 2025 | clinicaltrials |
| NCT03797625 | Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas | completed | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05101629 | Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy | completed | Phase 2 | 32 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03755141 | Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer | completed | Phase 2 | 109 | National Cancer Center, KoreaOTHER_GOV | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05632848 | Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients | completed | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2025 | clinicaltrials |
| NCT01781728 | Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma | completed | Phase 2 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06355024 | Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer | completed | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT02940496 | Pembrolizumab (MK-3475) in Hepatocellular Carcinoma | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT03117309 | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 164 | Michael B. Atkins, MDOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT00832429 | Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03382561 | Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 160 | National Cancer Institute (NCI)NIH | 1 | Jul 3, 2025 | clinicaltrials |
| NCT02723331 | Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates | completed | Phase 2 | 48 | Academic Thoracic Oncology Medical Investigators ConsortiumINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03781934 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | completed | Phase 1 / Phase 2 | 53 | MedivirINDUSTRY | 4 | Jul 1, 2025 | clinicaltrials |
| NCT04400188 | A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03106415 | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03094052 | Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | completed | Phase 2 | 11 | University of California, San FranciscoOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT03357757 | Avelumab With Valproic Acid in Virus-associated Cancer(LATENT) | completed | Phase 2 | 39 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT01673906 | 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours | completed | Phase 2 | 142 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 2 | Jun 24, 2025 | clinicaltrials |
| NCT04420598 | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease(DEBBRAH) | completed | Phase 2 | 41 | MedSIROTHER | 2 | Jun 24, 2025 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT04400474 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study(CABATEN) | completed | Phase 2 | 93 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT02368886 | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 123 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT03642067 | Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer | completed | Phase 2 | 59 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT04548440 | Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients | completed | Phase 2 | 50 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer(MAHOGANY) | completed | Phase 2 / Phase 3 | 82 | MacroGenicsINDUSTRY | 9 | Jun 8, 2025 | clinicaltrials |
| NCT04554836 | MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab | completed | Phase 2 | 6 | TheraOpOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04616196 | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | completed | Phase 1 / Phase 2 | 25 | Nektar TherapeuticsINDUSTRY | 1 | Jun 8, 2025 | clinicaltrials |
| NCT03297593 | Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 74 | Swiss Cancer InstituteOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT04358237 | Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.(LUPER) | completed | Phase 1 / Phase 2 | 28 | Antonio Calles BlancoOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03317327 | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors(REPORT) | completed | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT05499065 | Real-time Margin Assessment in Head and Neck Cancer(LIGHTNING) | completed | Phase 2 | 23 | University Medical Center GroningenOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06312670 | Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer | completed | Phase 2 | 13 | Pedro Barata, MD, MScOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT02760498 | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 432 | Regeneron PharmaceuticalsINDUSTRY | 8 | May 28, 2025 | clinicaltrials |
| NCT03108131 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | completed | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT04337970 | Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT02713386 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 147 | NRG OncologyOTHER | 1 | May 25, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 8, 2025source: clinicaltrials